Douglas F. Kling
Known title: Chief Operating OfficerCIK: 0001699022
Associated companies
Transaction History
| NAMS | ▲ Buy | Option Exercise | 51,043 | $556K | 7/16/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 51,043 | $1.1M | 7/16/2025 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 47,569 | $519K | 7/15/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 44,025 | $941K | 7/15/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 3,544 | $78K | 7/15/2025 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 78,101 | $781K | 6/16/2025 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 21,899 | $239K | 6/16/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 81,891 | $1.6M | 6/16/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 18,109 | $358K | 6/16/2025 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 100,000 | $1.0M | 5/15/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 100,000 | — | 5/15/2025 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 100,000 | $1.0M | 4/15/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 910 | — | 4/15/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 99,090 | — | 4/15/2025 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 16,539 | $0 | 3/26/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 16,539 | — | 3/26/2025 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 88,112 | — | 3/17/2025 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 11,888 | $119K | 3/17/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 100,000 | — | 3/17/2025 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 9,218 | — | 2/19/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 9,218 | — | 2/19/2025 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 90,782 | — | 2/18/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 90,782 | — | 2/18/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 4,664 | — | 1/30/2025 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 13,578 | — | 1/30/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 8,914 | — | 1/30/2025 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 56,863 | — | 1/29/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 56,863 | — | 1/29/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 20,237 | — | 1/28/2025 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 25,385 | — | 1/28/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 5,148 | — | 1/28/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 23,815 | — | 1/27/2025 | View on chart |
| NAMS | ▲ Buy | Option Exercise | 104,174 | — | 1/27/2025 | View on chart |
| NAMS | ▼ Sell | Open Market | 80,359 | — | 1/27/2025 | View on chart |
| NAMS | ▲ Buy | Grant | 44,000 | — | 1/7/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
RBC Capital Lowers Target to $42 for NAMS
RBC Capital has kept its outperform rating for NewAmsterdam Pharma (NAMS) but cut its price target to $42. The new target sits at the top of the 52‑week range and near the current support level of $35.04. The stock’s RSI of 33.5 suggests it is in an oversold zone, which may influence short‑term trading activity. Analysts still see upside potential, but the lowered target reflects a more cautious outlook.
RBC Capital Lowers Target to $42 for NAMS. RBC Capital has kept its outperform rating for NewAmsterdam Pharma (NAMS) but cut its price target to $42. The new target sits at the top of the 52‑week range and near the current support level of $35.04. The stock’s RSI of 33.5 suggests it is in an oversold zone, which may influence short‑term trading activity. Analysts still see upside potential, but the lowered target reflects a more cautious outlook.